Early cancer screening company Aimisen Life Technology closes multi-million-yuan Series A financing

Wuhan-based Aimisen Life Technology has raised tens of millions of yuan in Series A financing round, and the investor is CCB Medical Growth Fund. Proceeds from the fresh round will be used to accelerate the development and market expansion of the company’s early cancer detection products.

Wuhan-based Aimisen Life Technology has raised tens of millions of yuan in Series A financing round, and the investor is CCB Medical Growth Fund. Proceeds from the fresh round will be used to accelerate the development and market expansion of the company’s early cancer detection products.

Prior to this, the company has received investment from Hybribio Biotech, a leading cervical cancer screening and detection company in China.

Established in 2015, Aimisen Life Technology is a developer of early cancer screening technology focusing on colorectal cancer, cervical cancer, esophageal cancer, endometrial cancer. The company researches and develops early cancer detection products by utilizing epigenetics, nanomaterials, bioinformatics, big data technology and artificial intelligence analysis, enabling doctors to detect, diagnose and treat early cancer accurately.

“In the past two years, cancer early screening companies have been highly sought after by the capital market. Aimisen has always upheld ” early, accurate, non-invasive and convenient “as the product concept. At present, the company has completed development of early cancer detection products for colorectal cancer, cervical cancer, esophageal cancer, endometrium cancer and other cancers. At the same time, the company has beenexpanding R&D of other early cancer screening products. “Zhang Lianglu, founder of Amysen, said.

Disclaimer: This is an article created by Michael Liang for Chinasdg.org. You can find the original article here: https://chinasdg.org/2020/05/04/early-cancer-screening-company-aimisen-life-technology-closes-multi-million-yuan-series-a-financing/.

Leave a Reply

Please Login to Comment